Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

Saved in:

Bibliographic Details
Published in:	The Pediatric infectious disease journal Vol. 18; no. 3; pp. 223 - 231
Main Authors:	MEISSNER, H CODY, WELLIVER, ROBERT C, CHARTRAND, STEPHAN A, LAW, BARBARA J, WEISMAN, LEONARD E, DORKIN, HENRY L, RODRIGUEZ, WILLIAM J
Format:	Journal Article
Language:	English
Published:	Baltimore, MD Lippincott Williams & Wilkins, Inc 01-03-1999 Philadelphia, PA Lippincott Hagerstown, MD
Subjects:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Human viral diseases Humans Infant Infant, Newborn Infant, Premature Infectious diseases Medical sciences Palivizumab Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Viruses - immunology Risk Factors Viral diseases Viral diseases of the respiratory system and ent viral diseases Human respiratory syncytial virus Indication Vaccination Infant Monoclonal antibody Paramyxoviridae Prevention Palivizumab Heart disease Obstructive pulmonary disease Pneumovirus Pancreatic disease Human Lung disease Pneumovirinae Congenital Respiratory disease Metabolic diseases Cystic fibrosis Immune deficiency Recommendation Genetic disease Asthma Virus Immunoprophylaxis Mononegavirales Prematurity Risk factor Digestive diseases Pharmacokinetics Pneumopathy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0891-3668 1532-0987
DOI:	10.1097/00006454-199903000-00004